Across 49 CTIS depression/MDD Phase II–III trial records from 2024–2026, the dataset contains 600 site allocations and 7,193 planned participants. Phase III is the dominant operational segment, accounting for 486 of 600 site allocations and 5,354 of 7,193 participants, while Phase II contributes a smaller but more geographically varied early-development footprint.
Phase III records account for 33 of 49 trials, 486 of 600 site allocations, and 5,354 of 7,193 planned participants. Phase II contributes 16 of 49 records, 114 site allocations, and 1,839 planned participants.
For sponsors planning depression/MDD execution, competitive pressure is highest in late-stage site networks: Phase III absorbs more than three quarters of the participant burden and over four fifths of site allocations.
The most recurrent site listings are concentrated in Central and Eastern Europe, with Bulgaria, Poland, Czechia, Slovakia, and Hungary supplying several repeat psychiatric research sites. The leading visible site was Medical Center Hera EOOD, appearing 8 times across Phase II–III site listings.
| Rank | Site | Country | Listings |
|---|---|---|---|
| 1 | Medical Center Hera EOOD | Bulgaria | 8 |
| 2 | Mental Health Center Sofia EOOD | Bulgaria | 5 |
| 3 | Clintrial s.r.o. | Czechia | 4 |
| 4 | Medical Center Intermedica Ltd. | Bulgaria | 4 |
| 5 | PsychoLine s.r.o. | Slovakia | 4 |
| 6 | Crystal Comfort s.r.o. | Slovakia | 4 |
| 7 | Semmelweis University | Hungary | 3 |
| 8 | Clinexpert Kft. | Hungary | 3 |
| 9 | Processus Kft. | Hungary | 3 |
| 10 | Hospital Clinic de Barcelona | Spain | 3 |
The most repeatable operational footprint is not only in academic hospitals. Dedicated psychiatric clinics and private research centers appear repeatedly, which suggests that depression/MDD recruitment depends heavily on specialized outpatient networks.
In Phase II, 13 countries account for 114 site allocations and 1,839 planned participants. Norway leads by planned participants with 230 of 1,839, followed by Denmark with 220, Sweden with 214, Poland with 211, and Czechia with 188.
Phase II depression/MDD development is not concentrated in one dominant country. The top five countries account for 1,063 of 1,839 planned participants, or 57.8%, suggesting that early-stage recruitment is distributed across multiple Nordic, Central European, and Eastern European networks.
Major depressive disorder is the dominant label in the cohort, with related depression subtypes including treatment-resistant depression, bipolar depression, chronic depression, postpartum/perinatal depression, and seasonal affective disorder. Phase II contains 16 trial records, including 8 records explicitly using major depressive disorder and 5 records including treatment-resistant depression.
The operational opportunity is broad depression, but the highest-value recruitment capability is likely in MDD and treatment-resistant depression, where protocol volume and site reuse are strongest.
MDD means major depressive disorder. TRD means treatment-resistant depression. Site allocations count country-level site entries as reported in CTIS geography records; planned participants are summed from country-level or trial-level planned participant fields.